ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc.

April 18, 2007 16:10 ET

ProMetic Announces its Annual General Shareholders Meeting

MONTREAL, QUEBEC--(CCNMatthews - April 18, 2007) - ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI) will host its Annual and Special Shareholders' Meeting on Wednesday, May 2, 2007 at 10:30 a.m. (EDT). The Annual and Special Meeting will be held at the Montreal Museum of Fine Arts (1379 Sherbrooke Street West, Montreal).

Mr. Pierre Laurin, President and CEO and several executives of the Company's subsidiaries will speak about ProMetic's current and forthcoming programs, more specifically:

- Dr. Christopher Penney, CSO of ProMetic BioSciences Inc. will be providing an update on the clinical plan for PBI-1402 and the oncology pipeline;

- Dr. Steve Burton, CEO of ProMetic BioSciences Ltd will be providing an update on the strategic and financial performance of the UK subsidiary;

- Dr. Peter Edwardson, VP of PRDT (Pathogen Removal and Diagnostic Technologies Inc.) will give an overview of the activities surrounding the launch of the prion capture filter;

- Dr. Chris Bryant, COO of ProMetic BioTherapeutics, Inc, will update the shareholders on the latest agreement with Kedrion and other forthcoming agreements with plasma fractionators;

- Mr. Christian Frayssignes, CEO of BSafE Innovations Inc. will present the program to develop and launch the first generation product for the detection of Mad Cow Disease.

The Corporate presentations will be followed by a cocktail where guests and shareholders will have the opportunity of meeting members of the management and scientists who will be gathered for the occasion. For those who are unable to attend in person, the Company will simultaneously webcast the presentation from its website at

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ enabling technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the UK, the USA and Canada, manufacturing facilities in the UK and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the Company's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of the Company's Annual Information Form for the year ended December 31, 2006, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason.

Contact Information